Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.
Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board
Mingari, Maria Cristina;Pietra, Gabriella;Moretta, Lorenzo
2019-01-01
Abstract
Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731–1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
60. TREND in Immunol, 2019 .pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
740.17 kB
Formato
Adobe PDF
|
740.17 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
